Mark Levis, MD, PhD, currently serves as a Professor of Oncology and the Program Leader for the Hematologic Malignancies and Bone Marrow Transplant Program at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine in Baltimore, MD.
Prof. Levis received his medical degree from the University of California San Francisco School of Medicine in San Francisco, CA, in 1994. He completed a residency in internal medicine and a fellowship in medical oncology at the John Hopkins University School of Medicine in 1997 and 2002 respectively.
Prof. Levis has earned numerous awards including the ASCO Advanced Clinical Research Award, and has conducted many talks, mentorships and teaching lectures. He has also contributed extensively to numerous papers published in the top journals in his field, including Leukemia, Blood and the New England Journal of Medicine. Prof Levis is a member of the Leukemia and Lymphoma Society, the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA).
Speaking on molecularly targeted therapy for leukemia
Prof. Levis’ research focuses on the development of molecularly targeted therapies for leukemia, particularly those targeting the FLT3 signaling pathway. He is actively involved in the pre-clinical development of these therapies, and is particularly interested in translating this research into clinical practice.